Skin clinics were already a growing retail category. Then came “Ozempic face”

Demand for GLP-1 drugs is soaring as Australians turn to the newly approved products, Wegovy and Ozempic, designed to treat diabetes and obesity – but it also has the potential to create a large market for fillers. After watching how demand for GLP-1 drugs played out in the US market and the discourse that followed online around some of the physical side effects, Australian clinics are already anticipating increased demand for injectables. The filler fix Treatments such as cheek fillers and wr

This content is for IR Pro subscribers only.

Subscribe now to unlock an all-access pass.

IR Pro - monthly

$4 USD for the first 30 days. (Auto renews at $20 USD per month.)
  • Unlimited news access
  • Exclusive members only masterclasses (live and on-demand)
  • Weekly careers advice
  • Weekly and quarterly digital magazines delivered to your inbox
Subscribe now
Retailer’s choice

IR Pro - annual

$228 USD per year. (Auto renews annually)
  • Unlimited news access
  • Exclusive members only masterclasses (live and on-demand)
  • Weekly careers advice
  • Weekly and quarterly digital magazines delivered to your inbox
Subscribe now